By

Admin
DREAM​M 7 – A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab mafadotin (GSK2857916), Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma Recruitment to start from end of September (Phase III study from GSK) Information and how to...
Continue Reading
Come along to our Whangarei Myeloma Patient Seminar, hosted by Myeloma New Zealand and Leukaemia & Blood cancer New Zealand. During the evening, we will hear from Ken Romeril (Myeloma NZ) and Dr Sarah Poplar (Northland DHB) who will discuss some of the changes to come in 2020 for Myeloma treatment. Wednesday 12 August5.30pm to...
Continue Reading
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with multiple myeloma, a study suggests. Its researchers also report that lowering levels of a particular protein on myeloma cells, MCL-1, may make them more responsive to treatments for this cancer....
Continue Reading
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from the Experts: COVID-19 & Cancer Care for Patients.” Sponsored by Janssen and Pharmacyclics, the webinar was designed to provide those affected by chronic lymphocytic leukemia (CLL) and myeloma with information and updates as it pertained to...
Continue Reading
Patients with haematological cancers are at higher risk of COVID-19 infection and experience more severe disease compared to people with other cancers, say experts discussing the latest evidence on COVID-19. Speaking as part of an expert panel assembled for a COVID-19 webinar sponsored by Janssen-Cilag, Dr Benjamin Teh, an infectious diseases physician at the Peter...
Continue Reading
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people with COVID-19 pneumonia. The trial, named APLICOV, aims to recruit 160 patients across multiple sites in Spain and assess if Aplidin reduces the proportion of...
Continue Reading
A new study published in Leukemia revealed that researchers at the Institute of Cancer Research in London have found a new genetic test that could help doctors determine which patients with multiple myeloma are at “ultra high risk” of their cancer progressing aggressively in its early stages.1 The results of the research showed that a particular genetic...
Continue Reading
The immunosuppressant tocilizumab may be a promising option for myeloma patients with COVID-19, a case study from China suggests. Dr Changcheng Zheng, MD, of the University of Science and Technology of China and colleagues detailed the case of a 60-year-old man with multiple myeloma who was hospitalised with chest tightness and shortness of breath and subsequently...
Continue Reading
A new test can identify patients with multiple myeloma (MM) who have a high-risk genetic profile as well as multiple chromosomal abnormalities. In this subgroup of patients with ultra-high-risk MM, disease progression is increased, survival is very poor, and it is unlikely that patients will respond to a commonly used maintenance therapy, British researchers report. Read more...
Continue Reading
The COVID-19 pandemic continues to put a strain on healthcare delivery around the world. In this environment, haematologists are adapting their approach to treating multiple myeloma to minimise the risk to their patients. Last Thursday, Professor Miles Prince hosted a webcast to explore the issues surrounding management of patients during this challenging time. Joining him...
Continue Reading
1 2 3 23

Floor 7, 90 The Terrace
Wellington Central
New Zealand